Lilly Ventures β Full Portfolio
9 tracked investments Β· listed companies and verified rows first
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
BiotechHealthtechMilpitas, US
Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)
BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)
Co-investorsAisling CapitalCanaan PartnersJJDCStarfish Ventures
BiotechCharlottesville, US
TIMOTHY MACDONALD(Executive Officer)Anne Heldreth(Executive Officer)Andrew J Krouse(Executive Officer, Director)LLOYD GRAY(Executive Officer)
BoardHenry Skinner(Director)Sergei Petukhov(Director)
Co-investorsNovartis Venture Fund
BiotechIndianapolis, US
Steven E Hall(Executive Officer, Director)
BoardRichard Miller(Director)S Edward Torres(Executive Officer)Richard Kent(Director)
BiotechCambridge, US
Magdalene Moran, Ph.D.(Executive Officer)Bert Chenard, Ph.D.(Executive Officer)Russell Herndon(Executive Officer, Director)Tom Burke(Executive Officer)
BoardVincent Miles(Director)Jean George(Director)
Co-investorsLightstone VenturesNew Enterprise Associates (NEA)
The Longevity Science Foundation funds scientific research to address the biological drivers of women's health disparities, particularly ovarian aging and menopause.
BiotechHealthtechImpact & Social GoodLongevityZug, CH
Joshua C. Herring(President & CEO)in
Co-investorsLongeVCFounders FundKhosla VenturesThrive Capital
Lysosomal Therapeutics Inc.
BiotechCambridge, US
Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)
BoardSteven Hall(Director)Carole Nuechterlein(Director)Bernard Davitian(Director)
Co-investorsAtlas VentureHatteras Venture PartnersRoche Venture Fund
Quarry Thera is a biotech developing oral small-molecule medicines based on induced-proximity pharmacology, using molecular glues and heterobifunctional compounds.
BiotechDeep TechNew Haven, US
Craig Crews(Co-Founder & Scientific Advisor)inDan McHugh(Manager)Tim Shannon(CEO and Board Member)inJeanne Magram(Chief Scientific Officer)inKanak Raina(Chief Technology Officer)inSean Cassidy(Chief Financial Officer)in
Co-investorsYosemiteF-Prime CapitalCanaan Partners
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.
BiotechDeep TechHardwareHealthtechCambridge, US
Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)
BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)
Co-investorsLAVLilly Asia VenturesVivo Capital
Biotechnology company developing therapeutics that target the extracellular matrix in acute and chronic diseases.
BiotechSan Francisco, US
KENNETH N. HORNE(Executive Officer, Director)ALYSSA PANITCH(Director)JOHN PADERI(Director)KATE STUART(Executive Officer)
Co-investorsMitsui Global InvestmentAlly Bridge GroupInCube Ventures
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.